Sen. John Boozman Buys Eli Lilly and Company (NYSE:LLY) Stock

Senator John Boozman (R-Arkansas) recently bought shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed on September 12th, the Senator disclosed that they had bought between $1,001 and $15,000 in Eli Lilly and Company stock on August 11th.

Senator John Boozman also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of NVIDIA (NASDAQ:NVDA) on 8/22/2025.
• Sold $1,001 – $15,000 in shares of AbbVie (NYSE:ABBV) on 8/22/2025.
• Sold $1,001 – $15,000 in shares of Micron Technology (NASDAQ:MU) on 8/22/2025.
• Purchased $1,001 – $15,000 in shares of Eli Lilly and Company (NYSE:LLY) on 8/22/2025.
• Sold $1,001 – $15,000 in shares of AbbVie (NYSE:ABBV) on 8/11/2025.
• Purchased $1,001 – $15,000 in shares of Advanced Micro Devices (NASDAQ:AMD) on 8/7/2025.
• Purchased $1,001 – $15,000 in shares of iShares MBS ETF (NASDAQ:MBB) on 8/1/2025.
• Sold $1,001 – $15,000 in shares of iShares MSCI EAFE ETF (NYSEARCA:EFA) on 8/1/2025.
• Purchased $1,001 – $15,000 in shares of Goldman Sachs ActiveBeta Emerging Markets Equity ETF (NYSEARCA:GEM) on 8/1/2025.
• Purchased $1,001 – $15,000 in shares of iShares 7-10 Year Treasury Bond ETF (NASDAQ:IEF) on 8/1/2025.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock opened at $754.90 on Monday. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The firm has a market cap of $714.48 billion, a PE ratio of 49.34, a price-to-earnings-growth ratio of 1.05 and a beta of 0.47. The business’s fifty day simple moving average is $741.03 and its 200-day simple moving average is $775.51. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $942.35.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same quarter last year, the company earned $3.92 EPS. The business’s quarterly revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th were paid a $1.50 dividend. This represents a $6.00 annualized dividend and a dividend yield of 0.8%. The ex-dividend date of this dividend was Friday, August 15th. Eli Lilly and Company’s dividend payout ratio is 39.22%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of LLY. PNC Financial Services Group Inc. raised its position in Eli Lilly and Company by 97.5% in the 1st quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company’s stock worth $83,669,349,000 after purchasing an additional 50,002,551 shares during the last quarter. GAMMA Investing LLC increased its position in shares of Eli Lilly and Company by 103,831.6% in the 1st quarter. GAMMA Investing LLC now owns 14,866,380 shares of the company’s stock valued at $12,278,292,000 after buying an additional 14,852,076 shares in the last quarter. Laurel Wealth Advisors LLC increased its position in shares of Eli Lilly and Company by 78,621.2% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock valued at $9,005,392,000 after buying an additional 11,537,661 shares in the last quarter. Norges Bank bought a new stake in shares of Eli Lilly and Company in the 2nd quarter valued at $8,827,714,000. Finally, Nuveen LLC acquired a new position in Eli Lilly and Company in the 1st quarter worth $4,613,912,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have commented on LLY shares. Guggenheim reduced their target price on Eli Lilly and Company from $942.00 to $875.00 and set a “buy” rating on the stock in a report on Wednesday, August 13th. Cantor Fitzgerald reduced their target price on Eli Lilly and Company from $975.00 to $825.00 and set an “overweight” rating on the stock in a report on Wednesday, August 13th. Daiwa Capital Markets cut Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 price target on the stock. in a research report on Sunday, August 17th. Morgan Stanley reiterated an “overweight” rating and set a $1,135.00 price target (up from $1,133.00) on shares of Eli Lilly and Company in a research report on Thursday, July 10th. Finally, Leerink Partnrs cut Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 7th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus target price of $941.35.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, Director Gabrielle Sulzberger acquired 117 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The stock was bought at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the purchase, the director directly owned 2,703 shares in the company, valued at approximately $1,733,109.54. This represents a 4.52% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director J Erik Fyrwald purchased 1,565 shares of the stock in a transaction on Tuesday, August 12th. The stock was bought at an average cost of $642.33 per share, for a total transaction of $1,005,246.45. Following the completion of the acquisition, the director owned 74,578 shares in the company, valued at approximately $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders acquired 4,514 shares of company stock worth $2,894,841. Company insiders own 0.13% of the company’s stock.

About Senator Boozman

John Boozman (Republican Party) is a member of the U.S. Senate from Arkansas. He assumed office on January 3, 2011. His current term ends on January 3, 2029. Boozman (Republican Party) ran for re-election to the U.S. Senate to represent Arkansas. He won in the general election on November 8, 2022. Boozman won re-election in 2016. He faced Democrat Conner Eldridge, Libertarian Frank Gilbert, and write-in candidate Jason Tate in the general election. Arkansas’ U.S. Senate race was rated as safely Republican in 2016. Boozman began his political career in the U.S. House. He won a special election in 2001 and served in that position until his election to the Senate in 2010. Prior to his political career, Boozman worked as an optometrist. As of a 2014 analysis of multiple outside rankings, Boozman is an average Republican member of Congress, meaning he will vote with the Republican Party on the majority of bills. Below is an abbreviated outline of Boozman’s academic, professional, and political career: 2011-Present: U.S. Senator from Arkansas 2001-2011: U.S. Representative from Arkansas 1977: Graduated from Southern College of Optometry

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.